Quoin Pharmaceuticals Ltd ( (QNRX) ) has released its Q2 earnings. Here is a breakdown of the information Quoin Pharmaceuticals Ltd presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases. The company recently announced its financial results for the second quarter of 2025, highlighting significant clinical and regulatory progress.
In the second quarter of 2025, Quoin Pharmaceuticals reported positive clinical data from its ongoing studies on pediatric Netherton Syndrome and Peeling Skin Syndrome. The company also received important regulatory designations, including Orphan Drug Designation from the European Medicines Agency and Rare Pediatric Disease Designation from the U.S. FDA for its lead asset, QRX003. These achievements are expected to accelerate the development of QRX003.
Financially, Quoin reported a net loss of $3.7 million for the second quarter, primarily due to increased research and development expenses. The company had approximately $7.8 million in cash and equivalents, which is expected to support operations into the first quarter of 2026. Despite the losses, the company’s strategic advancements in clinical trials and regulatory approvals are promising.
Looking ahead, Quoin Pharmaceuticals remains focused on advancing its late-stage trials and expanding its global engagement. The company aims to deliver the first approved therapy for Netherton Syndrome, with additional studies planned for other indications in the coming months.